| http://www.w3.org/ns/prov#value | - Revenue grew 55 percent, to $62 million, mostly due to sales of Remodulin, a drug used to treat pulmonary arterial hypertension. *Vanda Pharmaceutical's first-quarter loss expanded to $19.2 million (72 cents) from $15.4 mlilion (61 cents).
|
